The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting.
Becker
R C
RC
Coronary Care Unit, University of Massachusetts Medical School, Worcester 01655.
Alpert
J S
JS
D001241:Aspirin / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000601:surgery; D012307:Risk Factors; D015912:Thrombolytic Therapy / Q000009:adverse effects
D002121:Calcium Channel Blockers; D006493:Heparin; D001241:Aspirin